Modulation of Plasmatic Matrix Metalloprotease 9: A Promising New Tool for Understanding the Variable Clinical Responses of Patients with Cystic Fibrosis to Cystic Fibrosis Transmembrane Conductance Regulator Modulators

Background: The most recent modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta(®)), has been shown to improve clinical outcomes in most patients with cystic fibrosis (PwCF). Unfortunately, the clinical benefits are sometimes variable; thus, improving our knowledge of the possible caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Capraro, Michela, Pedrazzi, Marco, De Tullio, Roberta, Manfredi, Marcello, Cresta, Federico, Castellani, Carlo, Averna, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488059/
https://www.ncbi.nlm.nih.gov/pubmed/37686190
http://dx.doi.org/10.3390/ijms241713384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488059/
https://www.ncbi.nlm.nih.gov/pubmed/37686190
http://dx.doi.org/10.3390/ijms241713384

Ejemplares similares